Company news
Sana Biotechnology, Inc. news in 2024
Sana Biotechnology, Inc.'s news releases, calls and decks from 2024, newest first.
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
December 1, 2024
Sana Biotechnology to Present at December 2024 Investor Conferences
November 24, 2024
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
November 7, 2024
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
November 3, 2024
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
September 29, 2024
Sana Biotechnology to Present at September 2024 Investor Conferences
August 28, 2024
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
August 25, 2024
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
August 7, 2024
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other G...
May 20, 2024
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
May 7, 2024
Sana Biotechnology to Present at May and June 2024 Investor Conferences
May 5, 2024
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 28, 2024
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
February 27, 2024
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
February 12, 2024
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 11, 2024
Sana Biotechnology Announces Pricing of Upsized Public Offering
February 7, 2024
Sana Biotechnology Announces Proposed Public Offering of Common Stock
February 6, 2024
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
January 4, 2024
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 2, 2024
Decks in 2024
- Investor Presentation (January 2024)
Investor deck · 36 slides · Jan 9, 2024